AQP4 and myeloid sarcoma: The number of enrolled participants for each disease group was as follows: 13 (2 male and 11 female) patients with AQP4-IgG-positive NMOSD, 26 (8 male and 18 female) patients with MOGAD, and 70 (17 male and 53 female) patients with MS.